Genetic Signatures
Australian molecular diagnostics firm leveraging 3base® technology for multiplex PCR infectious disease testing.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian molecular diagnostics firm leveraging 3base® technology for multiplex PCR infectious disease testing.
Infectious DiseasesGastrointestinal InfectionsRespiratory Infections
Technology Platform
3base® conversion chemically transforms cytosine to thymine, reducing DNA to a three‑base system (A, T, G) and enabling highly multiplexed, high‑homology real‑time PCR assays.
Opportunities
Expansion of multiplex PCR panels into new infectious disease areas and broader geographic markets, leveraging FDA clearances and the unique 3base® chemistry.
Risk Factors
Regulatory approval timelines, competition from larger diagnostics firms, and dependence on a single proprietary technology platform.
Competitive Landscape
Competes with Cepheid, Roche, Bio‑Rad and other multiplex PCR providers; differentiation stems from 3base®‑driven assay simplification and reduced primer complexity.